Advisory Board

people connected with lines
© Adobe Stock/sebastien montier

Our advisory board members are prominent experts from the spectrum of stakeholders involved in real-world evidence in the regulatory and health technology assessment context: regulatory agencies, European patient organisations, HTA, clinical experts, representatives for industry and representatives for payers.

Members

Christine Göppel
GKV-Spitzenverband – National Association of Statutory Health Insurance Funds, Germany


David Wormser
Novartis, Switzerland


Frauke Naumann-Winter
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) – Federal Institute for Drugs and Medical Devices, Germany


Jörg Zinserling
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) – Federal Institute for Drugs and Medical Devices, Germany


Iftekhar Khan
University of Warwick. Health Products Regulatory Authority (HPRA), Ireland


Lukas Enderlein 
Roche, Switzerland


Paulo Gonçalves
RD – Portugal (Union of Rare Disease Associations), Portugal


Phil Scordis
UCB Pharma UK, United Kingdom


Roland Linder
Techniker Krankenkasse, Germany


Tala Fakhouri
Food and Drug Administration (FDA), United States of America


Yannis Natsis
European Social Insurance Platform (ESIP), Belgium